PRESS RELEASES

Stillcanna Offers CBD White Label Services in Europe

Stillcanna Expands Product Offerings By Manufacturing THC-free CBD Distillate

Vancouver, British Columbia – (Accesswire) – Tuesday February 4, 2020 – Stillcanna Inc. (OTC:SCNNF) (CSE:STIL) (FRANKFURT:A2PEWA) ("STIL" or the "Company") is pleased to provide an array of white labeled finished products for its customers including products formulated with CBD Distillate (Honey Oil) that is Tetrahydrocannabinol (THC), pesticide, heavy metal and microbial free.

The recent successful deployment of the Company’s industrial scale centrifugal chromatography equipment at its Polish-based NEXUS facility equips Stillcanna with a broad range of new product offerings. Chromatography allows for the isolation and/or separation of specific molecules within a substance. Stillcanna uses chromatography to isolate and remove the THC molecule, enabling its THC-free CBD Distillate product offerings. The technology can also be calibrated to isolate any cannabinoid molecule present, which includes CBN, CBG and others that are popular in current scientific research for their potential health benefits.

With the technology in place to meet the CBD industry’s product requirements, Stillcanna is launching a white-label program, allowing customers to put their own brand and logo on stock Stillcanna CBD product offerings. These offerings will initially include tinctures in various sizes, concentrations and flavors; CBD Isolate packaged in 1g, 3g and 10g quantities; and CBD gel caps of varying sizes and strengths. In working with various nutraceutical, pharmaceutical and cosmetic manufacturers in Europe, the Company intends to broaden its CBD-infused product offerings to eventually also include lip balms, topicals for skin and muscle care, as well as vape products. For product inquiries, please email sales@investors.stillcanna.com.

In the latest edition of Stillcanna Stories, the Company’s seed-to-CBD process is highlighted as one of the only such operations in Europe. Controlling every aspect of production provides end users with the knowledge that the products are derived from the highest quality biomass that is heavy metal, pollutant and pesticide free; extracted and formulated in approved facilities; and adheres to EU-standard testing by both in-house and third party lab facilities. Of the many CBD retail brands available throughout Europe, very few formulate and package their own products. The majority of existing brands use a company like Stillcanna to supply them with a finished and branded CBD product with traceable documentation from seed-to-cbd. In conjunction with its white-label services, Stillcanna will still continue to supply larger consumers with its bulk CBD products.

“We have been eagerly anticipating the arrival and installation of this chromatography equipment,” stated Jason Dussault, CEO of Stillcanna. “There are a handful of suppliers in Europe that can offer companies a turnkey CBD solution to meet their pre-packaged CBD needs. While CBD continues to be our main focus, we cannot ignore the market potential that other cannabinoids hold. As the global research and scientific study of Cannabis and its compounds continues, we want to become a consistent and trusted source of specific cannabinoid profiles unique to our customer’s needs.”

The Company is also pleased to announce it has recently secured a membership in the European Industrial Hemp Association (EIHA) https://eiha.org/. Officially founded in 2005, EIHA is the only pan-European membership association in the industrial hemp sector. Membership spans 25 EU countries, and with over 200 active members represents the whole supply chain from seed-to-shelf. The association is active in advocating for reforms and updated regulations that promote a standardized framework for the hemp industry as a whole.

About Stillcanna Inc.
Stillcanna Inc. (CSE: STIL) www.investors.stillcanna.com is a Canadian early-stage life sciences company focused on the large scale manufacturing of CBD in Europe. The Company believes its proprietary intellectual property allows it to extract CBD at a lower cost. The Company has signed an initial extraction contract in Europe to be the exclusive extractor for Dragonfly Biosciences LLC, a United Kingdom-based supplier of CBD. The Company also recently completed the acquisition of Olimax NT SP. Z .O.O, a multi-generational hemp agricultural firm that is expected to increase the Company’s market share in the European CBD industry.

On Behalf of the Board

Jason Dussault, CEO
CONTACT:

Mauricio Inzunza
Mauricio@investors.stillcanna.com
1(844)-442-STILL (7845)

Cautionary Note Regarding Forward Looking Statements: This release includes certain statements and information that constitute forward-looking information within the meaning of applicable Canadian securities laws, including that the Company anticipates adding a broad range of new product offerings. And that the Company, can provide the scientific community a specific molecular profile of cannabinoids desired for research and customers can put their brand and logo on stock Stillcanna CBD product offerings.
Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should" or "would" occur. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the Company will initially provide tinctures in various sizes strengths and flavors, CBD Isolate packaged in one, three and ten gram jars, and CBD gel caps of varying sizes and strengths. And that the Company in working with various Nutraceutical, Pharmaceutical and Makeup manufacturers in Europe the company will broaden its CBD infused product offerings to include lip balms, topicals for skin and muscle care and vape products.

Although the Company considers these assumptions to be reasonable based on information currently available to it, they may prove to be incorrect, and the forward-looking statements in this release are subject to numerous risks, uncertainties and other factors that may cause future results to differ materially from those expressed or implied in such forward-looking statements.
Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not intend, and expressly disclaims any intention or obligation to, update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.

The CSE has not in any way passed upon the merits of and has neither approved nor disapproved the contents of this news release.

Subscribe to the Stillcanna Report